Compare HBR 60 80

Brief summary

An Investigator-initiated, multi-center, randomized controlled trial to compare the outcome of the ultrathin stent strut Supraflex Cruz stent to the thin stent strut Ultimaster Tansei stent in a PCI population at high bleeding risk.

Primary endpoints

Net Adverse Clinical Endpoints (NACE) defined as a composite of cardiovascular death, MI, TVR, stroke and major bleeding events (BARC 3 or 5) at 12 months.

CERC Services

  •  Kick-off activities
  • Clinical trials documentation
  • Project management
  • Clinical Events Committee (CEC) activities
  • Corelab activities 
  • Data monitoring Committee (DMC) activities
  • Statistical activities
  • Administrative tasks

Countries 

The Netherlands

Centers number

10 centers managed by CERC.